Ignite Creation Date:
2025-12-24 @ 5:46 PM
Ignite Modification Date:
2026-01-04 @ 3:55 PM
Study NCT ID:
NCT04101968
Status:
RECRUITING
Last Update Posted:
2025-05-31
First Post:
2019-09-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The GBA Multimodal Study in Parkinson's Disease
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010300', 'term': 'Parkinson Disease'}, {'id': 'D005776', 'term': 'Gaucher Disease'}], 'ancestors': [{'id': 'D020734', 'term': 'Parkinsonian Disorders'}, {'id': 'D001480', 'term': 'Basal Ganglia Diseases'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D009069', 'term': 'Movement Disorders'}, {'id': 'D000080874', 'term': 'Synucleinopathies'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D013106', 'term': 'Sphingolipidoses'}, {'id': 'D020140', 'term': 'Lysosomal Storage Diseases, Nervous System'}, {'id': 'D020739', 'term': 'Brain Diseases, Metabolic, Inborn'}, {'id': 'D001928', 'term': 'Brain Diseases, Metabolic'}, {'id': 'D008661', 'term': 'Metabolism, Inborn Errors'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D008064', 'term': 'Lipidoses'}, {'id': 'D008052', 'term': 'Lipid Metabolism, Inborn Errors'}, {'id': 'D016464', 'term': 'Lysosomal Storage Diseases'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D052439', 'term': 'Lipid Metabolism Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D049268', 'term': 'Positron-Emission Tomography'}], 'ancestors': [{'id': 'D014055', 'term': 'Tomography, Emission-Computed'}, {'id': 'D007090', 'term': 'Image Interpretation, Computer-Assisted'}, {'id': 'D003952', 'term': 'Diagnostic Imaging'}, {'id': 'D019937', 'term': 'Diagnostic Techniques and Procedures'}, {'id': 'D003933', 'term': 'Diagnosis'}, {'id': 'D007089', 'term': 'Image Enhancement'}, {'id': 'D010781', 'term': 'Photography'}, {'id': 'D011877', 'term': 'Radionuclide Imaging'}, {'id': 'D014054', 'term': 'Tomography'}, {'id': 'D003947', 'term': 'Diagnostic Techniques, Radioisotope'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Blood sample'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'CROSS_SECTIONAL', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 25}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2019-05-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-05', 'completionDateStruct': {'date': '2025-12-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-05-27', 'studyFirstSubmitDate': '2019-09-16', 'studyFirstSubmitQcDate': '2019-09-20', 'lastUpdatePostDateStruct': {'date': '2025-05-31', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-09-24', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Acetylcholinesterase activity', 'timeFrame': 'baseline', 'description': '11C-PMP PET'}, {'measure': 'Tau protein deposition', 'timeFrame': 'baseline', 'description': '11C-PBB3 PET'}, {'measure': 'Dopaminergic denervation', 'timeFrame': 'baseline', 'description': '11C-DTBZ PET'}, {'measure': 'neuroQWERTY index', 'timeFrame': 'baseline', 'description': 'Typing analysis'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Parkinson'], 'conditions': ['Parkinson Disease', 'GBA Gene Mutation', 'Gaucher Disease']}, 'descriptionModule': {'briefSummary': "This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.", 'detailedDescription': "Study Rationale: People who have a mutation in the GBA gene have a higher risk of developing Parkinson's disease (PD) and, if they have PD, are more likely to have cognitive decline and dementia. Cognitive problems in people with PD is related to dysfunction of the brain chemical acetylcholine and likely to the accumulation of the tau protein in the brain. Another observation in previous studies is that analyzing the patterns of typing into a computer can help differentiate healthy people from people with PD.\n\nHypothesis: The investigators hypothesize that people with GBA-related PD will have higher acetylcholine dysfunction and tau accumulation compared with non-GBA patients, and that these changes may start in the asymptomatic phase (i.e., people with the mutation but without symptoms of PD). The investigators also believe that the investigators will be able to detect subjects with higher degree of dopamine loss just by analyzing the way they type into a computer.\n\nStudy Design: The investigators will recruit 25 subjects with a GBA mutation (10 subjects with PD and 15 asymptomatic carriers). All the participants will have a clinical evaluation and a typing session, and subsequently will undergo a brain MRI and three PET scans with a tau tracer, an acetylcholine tracer, and a dopaminergic tracer. A blood sample will also be taken for the analysis of GCase (the enzyme related to the GBA mutation).\n\nImpact on Diagnosis/Treatment of Parkinson's Disease: The results will help understand the changes that take place in the brain of people with GBA-related Parkinson's disease, and hopefully will shed light also on the pathophysiology of non-GBA-related Parkinson's, as well as on the molecular correlates of cognitive decline, especially in its early stage. The typing data along with dopaminergic imaging will clarify the possible role of using typing patterns to identify subjects with early stage Parkinson's disease.\n\nNext Steps for Development: The findings of this study may help identify biomarkers for cognitive decline in early Parkinson's disease, with a potential role in clinical trials. Also, if the hypothesis on the typing is confirmed, this approach may be studied in larger cohorts for early diagnosis of Parkinson's in other at-risk populations."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'People with a known pathogenic GBA gene mutation with or without PD.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;\n* age 18 to 80 years.\n\nExclusion Criteria:\n\n* co-occurrence of other neurological disorders;\n* implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);\n* severe claustrophobia;\n* intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);\n* ongoing treatment with cholinergic drugs'}, 'identificationModule': {'nctId': 'NCT04101968', 'briefTitle': "The GBA Multimodal Study in Parkinson's Disease", 'organization': {'class': 'OTHER', 'fullName': "Pacific Parkinson's Research Centre"}, 'officialTitle': 'Multimodal Molecular Imaging and Biometric Analysis in GBA-PD and Asymptomatic GBA-mutation Carriers', 'orgStudyIdInfo': {'id': '16451'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'GBA-PD', 'description': "People with Parkinson's disease who are known heterozygous carriers of pathogenic GBA gene mutations.", 'interventionNames': ['Diagnostic Test: PET scan', 'Diagnostic Test: neuroQWERTY']}, {'label': 'Asymptomatic GBA', 'description': 'Known heterozygous carriers/obligated carriers of pathogenic GBA gene mutations.', 'interventionNames': ['Diagnostic Test: PET scan', 'Diagnostic Test: neuroQWERTY']}], 'interventions': [{'name': 'PET scan', 'type': 'DIAGNOSTIC_TEST', 'description': '3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.', 'armGroupLabels': ['Asymptomatic GBA', 'GBA-PD']}, {'name': 'neuroQWERTY', 'type': 'DIAGNOSTIC_TEST', 'description': 'Analysis of free-text typing in a computer and/or a touch-screen device.', 'armGroupLabels': ['Asymptomatic GBA', 'GBA-PD']}]}, 'contactsLocationsModule': {'locations': [{'zip': '97239', 'city': 'Portland', 'state': 'Oregon', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Matthew Brodsky, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Oregon Health & Science University', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '98108-1595', 'city': 'Seattle', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Cyrus P Zabetian, MD, MS', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University of Washington', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'city': 'Vancouver', 'state': 'British Columbia', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Jess McKenzie', 'role': 'CONTACT', 'email': 'jess.mckenzie@ubc.ca', 'phone': '+1-604-822-7764'}, {'name': 'A Jon Stoessl, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': "Pacific Parkinson's Research Centre | University of British Columbia", 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}], 'centralContacts': [{'name': 'Jessamyn McKenzie', 'role': 'CONTACT', 'email': 'jess.mckenzie@ubc.ca', 'phone': '6048227764'}], 'overallOfficials': [{'name': 'Michele Matarazzo, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "Pacific Parkinson's Research Centre | University of British Columbia"}, {'name': 'A. Jon Stoessl, CM, MD, FRCPC, FCAHS', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "Pacific Parkinson's Research Centre | University of British Columbia"}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': "Pacific Parkinson's Research Centre", 'class': 'OTHER'}, 'collaborators': [{'name': 'University of British Columbia', 'class': 'OTHER'}, {'name': 'University of Washington', 'class': 'OTHER'}, {'name': 'Oregon Health and Science University', 'class': 'OTHER'}, {'name': 'Simon Fraser University', 'class': 'OTHER'}, {'name': "Michael J. Fox Foundation for Parkinson's Research", 'class': 'OTHER'}, {'name': 'Silverstein Foundation', 'class': 'UNKNOWN'}, {'name': 'Weston Brain Institute', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}